Results 61 to 70 of about 98,172 (269)

Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. [PDF]

PLoS ONE, 2013
BCR-ABL kinase domain inhibition can be used to treat chronic myeloid leukemia. The inhibitors such as imatinib, dasatinib and nilotinib are effective drugs but are resistant to some BCR-ABL mutations.
Karunakar Tanneeru, Lalitha Guruprasad
doaj   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

The Hsp90β Isoform: An Attractive Target for Drug Development

Medicinal Research Reviews, EarlyView.
ABSTRACT The beta isoform of 90 kDa heat shock protein (Hsp90β) plays a critical role in maintaining cellular proteostasis by assisting in the folding and refolding of proteins, which is essential for both normal cellular function and stress response.
Subhabrata Chaudhury, Terin D'Amico, Brian S. J. Blagg   +2 more
wiley   +1 more source

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

Cancer Research, 2005
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in ...
T. O'hare, D. Walters, Eric P. Stoffregen, Taiping Jia, P. Manley, J. Mestan, S. Cowan-Jacob, F. Lee, M. Heinrich, M. Deininger, B. Druker   +10 more
semanticscholar   +1 more source

Nanosensors in Leukemia Management: Pioneering Real‐Time Biomarker Detection for Precision Oncology

Nano Select, EarlyView.
This review highlights pioneering nanosensors designed for real‐time leukemia biomarker detection, integrating advanced nanomaterials such as liposomes, polymeric nanoparticles and quantum dots. It examines electrochemical, optical and magnetic detection mechanisms, the applications across AML, ALL, CML, and CLL subtypes, and clinical translation ...
Hamed Soleimani Samarkhazan, Mohammad Navid Khaksari, Amirhossein Mirzazadeh, Mohammad Siavashi, Niloofar Pilehvari, Mohammad Hossein Mohammadi   +5 more
wiley   +1 more source

The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia

Cell Communication and Signaling
Background Abnormally expressed BCR/ABL protein serves as the basis for the development of chronic myeloid leukaemia (CML). The F-actin binding domain (FABD), which is a crucial region of the BCR/ABL fusion protein, is also located at the carboxyl end of
Renren Zheng, Wei Wei, Suotian Liu, Dachuan Zeng, Zesong Yang, Jie Tang, Jinfeng Tan, Zhenglan Huang, Miao Gao   +8 more
doaj   +1 more source

Thiostrepton Suppresses the Progression of Rhabdomyosarcoma by Inhibiting the PI3K‐AKT Signaling Pathway

Pediatric Discovery, EarlyView.
The study establish TST as a multi‐mechanism PI3K‐AKT inhibitor for refractory RMS while validating Cmap‐driven drug repurposing for pediatric oncology. ABSTRACT Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma with 5‐year survival below 30% in high‐risk/metastatic cases, was investigated through integrated bioinformatics analysis (
Yu Wang, Peng Hong, Zhiqiang Gao, Wei Ma, Zaihong Hu, Jie Lin, Kongkong Cui, Qinlin Shi, Xiao‐Mao Tian, Guanghui Wei   +9 more
wiley   +1 more source

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Journal of Clinical Investigation, 2011
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition.
A. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. Deininger, B. Druker   +5 more
semanticscholar   +1 more source

Concomitant occurrence of BCR-ABL and JAK2V617F mutation [PDF]

Blood, 2011
To the editor: In a recent issue of the journal, Makishima et al[1][1] reported on the occurrence of mutations typically associated with Philadelphia-chromosome (Ph1) negative myeloproliferative (MPN)/ myelodysplastic neoplasms in 54 patients with typical chronic myelogenous leukemia (CML ...
PIERI, LISA, SPOLVERINI, AMBRA, SCAPPINI, BARBARA, U. Occhini, S. Birtolo, BOSI, ALBERTO, F. Albano, C. Fava, VANNUCCHI, ALESSANDRO MARIA   +8 more
openaire   +6 more sources

Current Insights of the Potential Plant Bioactive Compounds on Modulating the mTOR Signaling Pathway in Regulating Oncological Disorders

Phytotherapy Research, EarlyView.
ABSTRACT Deregulation of the mechanistic target of the rapamycin (mTOR) pathway plays an important role in cancer genesis and progression, making it an attractive target for cancer treatment. Disrupting the mTOR pathway contributes to uncontrolled cell growth, increased proliferation, and enhanced cell survival, all of which are hallmarks of cancer ...
Sonali Khanal, Manjusha Pillai, Md. Shimul Bhuia, Muhammad Torequl Islam, Onkar Sharma, Rachna Verma, Eugenie Nepovimova, Kamil Kuca, Dinesh Kumar, Raihan Chowdhury   +9 more
wiley   +1 more source